Healthcare Human Factors

Industrial Impact

Mind Medicine (MindMed) Inc. | December 30, 2021

Mind Medicine Inc. a leading biotech company developing psychedelic-inspired therapies, announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. "On behalf of the Board of Directors and Executive team, I would like to thank Bradford for his contributions to the Company and wish him all the best in his future endeavors. We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under...

Industrial Impact

Cantargia AB | July 05, 2022

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Medical

CosmosID | June 22, 2022

CosmosID®, an American provider of end-to-end microbiome platforms and award-winning metagenomics services, announced entering into a microbiome partnership with a clinical-stage biotechnology company developing a new class of precision-engineered bacteriophage treatments, Locus Biosciences, Inc. With this partnership, CosmosID focuses on providing its GCP-compliant and CLIA-certified laboratory services for Locus' clinical trial initiatives in the microbiome field. ...

Industrial Impact

Enveric Biosciences, Inc | July 14, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...